

# Cancer Informatics in the 'new NHS': PHE and NCIN 18 months on....

Mick Peake Clinical Lead, National Cancer Intelligence Network

# The Health & Social Care Bill 2012: Two New Organisations from April 2013

#### NHS England

- "The purpose of NHS England is to use the £80bn commissioning budget to secure the best possible outcomes for patients"
- To ensure the whole commissioning architecture is in place; will also commission some services directly

#### Public Health England (PHE)

- Information & Intelligence to support local PH and public making healthier choices
- National Leadership to PH, supporting national policy
- Development of PH workforce
- A civil service function, not NHS



#### **Data Drivers**

- Government
  - A spotlight on the role of data and transparency
- Commissioning
  - NHS Outcomes Framework
- Regulation
  - New regulation framework (CQC & Monitor)
- The 'public', patients and families
  - (e.g. 'Friends and family test')



# Providers of information in the new NHS

- Main sources/providers
  - Health & Social Care Information Centre (HSCIC)
  - National Audits
  - ONS
  - PHE (Civil Service)- Cancer Registries
  - NHS England Business Intelligence Teams (ATS/CSU)
- Information Intermediaries (e.g. CRUK, Dr Foster, MacMillan)



## **Public Health England**



#### **Knowledge Directorate**

- National Cancer Registration Service
- Analytical workforce from 8 registries moved into regional Knowledge and

Intelligence Teams (KITs)

- SSCRG Lead Area Work Programmes
- Local contribution
- Health Intelligence Networks (HINs):
  - Mental Health, Maternal & Child Health,
     Cardiovascular & Diabetes, End of Life, NCIN

## Public Health England: Emerging 'Intelligence' Structures

Public Health England Chief Knowledge Officer (Prof. John Newton)

Disease Registration Service (Dr Jem Rashbass) Health Intelligence Networks (Prof. Brian Ferguson)

Knowledge & Intelligence Teams (KITs)

National Cancer
Intelligence Network
Chris Carrigan

PHE Information Services Chris Carrigan




#### The English National Cancer Registration System

- Comprehensive data collection and quality assurance over the entire cancer care pathway on all patients treated in England
- Single national system across England
- Routine electronic sources in registry practice
- Single integrated workforce split off from the analytical work force
- Director of Disease Registration
- Evolving operational links with hospital leads
- Pan-England roll-out completed September 2013




# National Cancer Registration Service: Data Sources





#### NCRS - ENCORE

#### (English National Cancer Online Registration Environment)



### NHS England – current structures

- One national office in Leeds
- 4 regions, directly commission primary care & specialist services
- 10 specialised commissioning hubs within 27 Area Teams
- 12 clinical senates clinical advice/leadership at strategic level to CCGs and HWBs
- 12 strategic Clinical Networks (up to 5 years)
- 12 Academic Health Science Networks
- 18 Commissioning Support Units support to CCGs
- 27 Area Teams will support CCG development
- 211 Clinical Commissioning Groups (CCGs)
- 152 Health and Well Being Boards



## **Specialist Commissioning**

- National Service Specifications (e.g. radiotherapy, chemotherapy, mesothelioma, upper GI cancer, specialised urology, surgery....)
- Clinical Reference Groups 12 relating to cancer (e.g. chemotherapy, radiotherapy, upper GI surgery, thoracic surgery......)

.....under review

### **Clinical Reference Groups - cancer**

- Radiotherapy Peter Kirkbride and Adrian Crellin
- PET-CT Wai Lup Wong
- Specialised Cancer Sean Duffy
- Blood and Marrow transplantation Antonio Pagliuca
- Thoracic surgery *Richard Page*
- Upper GI Surgery William Allum
- Sarcoma Jeremy Whelan
- CNS tumours Paul Grundy
- Specialised urology Vijay Sangar
- Complex gynaecological services vacant
- Chemotherapy *Peter Clark*
- Complex Head & Neck Peter Thomson
- Teenage and Young People Cancer Rachael Hough

# NHS Outcome Framework 2013/14 Dashboard

Overarohing indicators			
Overainming indicators	Latest data	Indicator value	Unit
1a.1 Potential Years of Life Lost (PYLL) from causes considered amenable to health care - Adults	2011	M - 2,157 F - 1,700	per 100,000 population
1a.II - Children and young people	2011	M - 616 F - 531	per 100,000 population
1b.I Life expectancy at 75 - Males	2010	11.3	period expectations
1b.II Life expectancy at 75 - Females	2010	13.1	life - years
Improvement areas			
1.1 Under 75 mortality rate from cardiovascular disease	2011	58.0	per 100,000 population
1.2 Under 75 mortality rate from respiratory disease	2011	23.5	per 100,000 population
1.8 Under 75 mortality rate from liver disease	2011	14.9	per 100,000 population
1.4 Under 75 mortality rate from cancer	2011	107	per 100,000 population
1.4.1 One-year survival from colorectal cancer "	2008-2010_11	74.4	%
1.4.II Five-year survival from colorectal cancer "	2008-2010_11	55.3	%
1.4.III One-year survival from breast cancer "	2008-2010_11	95.5	% female
1.4.lv Five-year survival from breast cancer "	2008-2010_11	84.3	% female
1.4.v One-year survival from lung cancer *	2008-2010_11	31.6	%
1.4.vl Five-year survival from lung cancer "	2008-2010_11	9.8	%
1.6 Excess under 75 mortality rate in adults with serious mental liness	2010/11	921	absolute gap per 100,000 population
1.8.I infant mortality	2011	4.2	per 1,000 births
1.6.II Neonatal mortality and stillbirths	2011	8.2	per 1,000 births
1.8.III Five-year survival from all cancers in children	Indicator to be developed		
1.7 Excess under 60 mortality rate in adults with a learning disability	Indicator to be developed		

Latest data	Indicator value	Unit
Jul12-Mer13	0.73	avg EQ-5D score
Jul12-Mer13	69.3	%
Jan-Mar13	11.8	% gap
2011/12	801	per 100,000 population
2011/12	321	per 100,000 population
Jul12-Mer13	0.8	avg EQ-5D score
Jan-Mar13	39.0	% gap
2011/12	46.0	%
	Jul12-Mer13 Jul12-Mer13 Jen-Mer13 2011/12 2011/12 Jul12-Mer13 Jen-Mer13	Lefsct data value Jul 12-Mer 13 0.73  Jul 12-Mer 13 09.3  Jen-Mer 13 11.8  2011/12 801  2011/12 321  Jul 12-Mer 13 0.8  Jen-Mer 13 0.8

8 Helping people to recover from epic	1 Preventing people
Overarching Indicators	
3a Emergency admissions for acute conditions that should not usually require hospital admission (all ages) 36 Emergency readmissions within 30 days of discharge from hospital improvement areas.	Overarching indicators  1a.i Potential Years of Li
Total health gain as assessed by patients for elective procedures - Hip replacement	causes considered amena
3.1.II – Knee replacement	Adults
3.1.III - Groin hemia	1a.ii - Children and youn
3.1.Iv – Varicose veins	1b.i Life expectancy at 75
3.1.v - Psychological therapies 3.2 Emergency admissions for children with	1b.ii Life expectancy at 7
lower respiratory tract infections	
3.3 An indicator on recovery from injuries and	Improvement areas
trauma  3.4 Proportion of stroke patients reporting an improvement in activity/lifestyle on the Modified Rankin Scale at 6 morths  3.5.1 Proportion of patients with a fragility fracture recovering to their previous levels of	1.1 Under 75 mortality rat cardiovascular disease 1.2 Under 75 mortality rat disease
mobility at 30 days  3.6.II Proportion of patients with a fragility fracture recovering to their previous levels of mobility at 120 days  3.8.I Proportion of older people (65 and over)	1.3 Under 75 mortality rat
a.s. Proportion or order people (es and over) who were still at home 91 days after discharge from hospital into reablement/rehabilitation services	1.4 Under 75 mortality rat
3.8.II Proportion offered rehabilitation following discharge from acute or community hospital	1.4.i One-year survival fro cancer *
	1.4.ii Five-year survival fr cancer *
	1.4.iii One-year survival f

#### **NHS Outcomes**

 Data displayed are for 2012/13 indicators as data for available

20XX indicates calendar year 20XX/XX indicates financial year

Prevent	ting peopl	le from dy	ing prema	turely

Overarching indicators			
-	Latest data	Indicator value	Unit
1a.i Potential Years of Life Lost (PYLL) from causes considered amenable to health care -     Adults	2011	M - 2,157 F - 1,700	per 100,000 population
1a.ii - Children and young people	2011	M - 616 F - 531	per 100,000 population
1b.i Life expectancy at 75 - Males	2010	11.3	period expectations of
1b.ii Life expectancy at 75 - Females	2010	13.1	life - years
Improvement areas			
1.1 Under 75 mortality rate from cardiovascular disease	2011	58.0	per 100,000 population
1.2 Under 75 mortality rate from respiratory disease	2011	23.5	per 100,000 population
1.3 Under 75 mortality rate from liver disease	2011	14.9	per 100,000 population
1.4 Under 75 mortality rate from cancer	2011	107	per 100,000 population
1.4.i One-year survival from colorectal cancer *	2006-2010_11	74.4	%
1.4.ii Five-year survival from colorectal cancer *	2006-2010_11	55.3	%
1.4.iii One-year survival from breast cancer *	2006-2010_11	95.5	% female
1.4.iv Five-year survival from breast cancer *	2006-2010_11	84.3	% female
1.4.v One-year survival from lung cancer *	2006-2010_11	31.6	%
1.4.vi Five-year survival from lung cancer *	2006-2010_11	9.8	%
1.5 Excess under 75 mortality rate in adults with serious mental illness	2010/11	921	absolute gap per 100,000 population
1.6.i Infant mortality	2011	4.2	per 1,000 births
1.6.ii Neonatal mortality and stillbirths	2011	8.2	per 1,000 births
1.6.iii Five-year survival from all cancers in children	Indicator to be developed		

# Clinical Commissioning Group Outcomes Indicator Set


#### 2013/14 under 75 mortality rate from cancer

- 1 and 5 year survival from all cancers
- 1 and 5 year survival from breast, lung & colorectal cancers

#### 2014/15 additional indicators for cancer

- cancers diagnosed via emergency routes
- 5 year survival children
- cancer stage at diagnosis
- cancers detected at stage 1 or 2
- 1 and 5 yr survival for lung, breast and colorectal cancers

### **HSCIC** Indicator Portal





#### National Cancer Intelligence Network

#### **Cancer Commissioning Toolkit**


Kath Yates \*

Updates Home Dashboards Comparisons Profiles Charts Background Home COMING Dashboards **Profiles** Charts Comparisons Making the data count Comparative reporting of data Improving outcomes Increase the value of data Compare your organisation/service, Understanding variation of both View or download trends to View a snapshot of data by organisation group to support quality, establish baselines & identify issues. patient experience & service deilvery benchmark along the patient pathway services & outcomes. using data indicators. by accessing in depth data. Background Help




### Cancer Commissioning Toolkit (CCT)

### - Colo-rectal cancer service profile






### Survival Index CCG within SCN





## Stage 1 & 2 by CCG





# **Emergency Presentation by CCG**

Home / Charts / Incidence / Proxy measure for emergency presentations for cancer Proxy measure for emergency presentations for cancer [=] Overview **Filters** View by Proportion of newly identified tumours first presenting as an emergency calculated from Inpatient **HES data** Cancer site **Emergency Presentation:** Download PDF Export to CSV CCG All England (99) 4 CCG(s) Selected NHS Aylesbury Vale CCG Show Confidence Interval 60 NHS Barking and Dagenham CCG (07L) Filter NHS Bristol CCG (11H) Percentage



# Two week wait referrals by CCG

**National Cancer Intelligence Network** 

#### **Cancer Commissioning Toolkit**

Background Dashboards Comparisons Profiles Charts Updates Home Home / Charts / Cancer Referrals / Cancer Referrals Cancer Referrals = Overview Filters Compare by Two Week Wait Referral Download PDF Lung **Organisation** Cancer type Export to CSV 100 Organisation level NHS Bassetlaw CCG (02Q) AT CCG Trust NHS Bath and North East Somerset CCG (11E) 80 NHS Birmingham Crosscity Organisation CCG (13P) NHS Birmingham South and 4 CCG(s) Selected Central CCG (04X) 60 Cancer type Lung 40

Kath Yates ▼



## Cancer waits 31 days

**National Cancer Intelligence Network** 

#### **Cancer Commissioning Toolkit**

**Profiles** Charts Background Updates Dashboards Comparisons Home / Charts / Cancer Waits / Cancer Waits Cancer Waits 🗐 Overview **Filters** Compare by 31 Day Wait Diagnosis to Treatment Download PDF Cancer type First treatment: 2014/15: Q1: First treatment: 2014/15: Q1: Export to CSV Skin: Modalities selected Gynae: Modalities selected Organisation level NHS Bassetlaw CCG (02Q) AT Trust NHS Bradford Districts CCG NHS Canterbury and Coastal Organisation CCG (09E) 3 CCG(s) Selected Cancer type 2 Cancer type(s) Selected Measure First treatment Percentage Percentage Modalities

Kath Yates ▼



## Cancer Waits 62 days

**National Cancer Intelligence Network** 

#### **Cancer Commissioning Toolkit**

Dashboards **Profiles** Charts Background Updates Comparisons Home Home / Charts / Cancer Waits / Cancer Waits Cancer Waits 🗐 Overview **Filters** Compare by 62 Day Wait Referral to Treatment First treatment: Breast: Modalities selected Download PDF Cancer type Export to CSV Organisation level Barnsley Hospital NHS Foundation Trust (RFF) Trust AT Barts Health NHS Trust 80 (R1H) Organisation 2 Trust(s) Selected 60 Cancer type Breast 40 Measure First treatment 20

Kath Yates ▼

#### **Datasets**

- Radiotherapy Dataset (RTDS), 2009.....
- Diagnostic Imaging Dataset (DIDs), 2012...
- Systemic Anti-Cancer Therapy Dataset (SACT), 2012....
- Cancer Outcomes & Services Dataset (COSD), 2013.....




# Examples of the clinical value of new data

- Demonstration of variation
- Teasing out the causes of variation
- Demonstrating value of specialisation
- Building data into quality improvement
- Adding outcome data into Peer Review
- Providing robust evidence behind National Guidelines and Quality Standards (NICE)
- Supporting 'intelligent commissioning'





#### NCRS BiobankLink Service





### **National Cancer Audits**

- National Lung, Colo-rectal and Head & Neck Cancer Audits all have contracts that expire at the end of 2014
- Re-tendering process underway smooth transition will be the main issue
- New Prostate Cancer Audit began 2014
- Breast cancer audit likely to be commissioned in 2015



### **National Cancer Audits**



- New model for national cancer audits
  - Partnership between NCRS and professional bodies
- Information governance and data QA managed by NCRS
  - Near-real-time data collection from MDTs
  - Data set largely collected as part of routine flows
- Continuous feedback to clinicians and MDTs
- NCRS produces linked audit datasets for analysis

# Feeding back: examples



- E Atlas
- Reports and data briefings
- Cancer Commissioning Toolkit
- Service & GP Profiles Sue Knights



# Public Health Cancer e-Atlas



Network rates

92

← → C \ www.ncin.org.uk/cancer\_information\_tools/eatlas/network/atlas.html?select=Eav&indicator=i0





Comparator to UK average rate

#### UK Cancer e-Atlas by cancer networks

#### Data being displayed: Prostate - Male Survival 5 Year

Select localities Export data

Select cancer network	Rate
Essex	82.9 %
Greater Manchester and Cheshire	81.4 %
Greater Midlands	80.2 %
Humber and Yorkshire Coast	80.5 %
Kent and Medway	81.9 %
Lancashire and South Cumbria	85.4 %
Merseyside and Cheshire	82.0 %
Mount Vernon	78.9 %
North East London	81.5 %
North London	87.1 %
North Trent	74.4 %
North West London	86.4 %
North of England	79.9 %
North of Scotland	80.8 %
Northern Ireland	82.9 %
Pan Birmingham	86.5 %
Peninsula	79.2 %
Scotland	80.1 %
South East London	81.5 %
South East Scotland	82.2 %
South West London	87.8 %
Surrey, West Sussex and Hampshire	83.7 %
Sussex	82.8 %
Thames Valley	88.0 %
United Kingdom	82.2 %
Wales	76.6 %
West of Scotland	78.2 %
Yorkshire Cancer Network	82.0 %





Cancer type





▶ Bladder

▶ Brain

▶ Breast

► Cervix

Colorectal (bowel)

► Kidney

▶ Leukaemia

Lung including trachea and bronchus

► Malignant melanoma of skin

Non-Hodgkin lymphoma

► Oesophagus

▶ Ovary

► Pancreas

▼ Prostate

Male Incidence\*

Male Mortality\*

Male Survival 1 Year

Male Survival 3 Year Male Survival 5 Year

▶ Stomach

▶ Uterus

■ North of England

Significantly lower than UK average 🔳 Not significantly different than UK average 🔸 Significantly higher than UK average 👂

North of England

Locality

UK average | Data value •

Incidence Mortality Survival

Information about the selected data item

\* Age-standardised

100



Relative survival is an estimate of the percentage of patients still alive five years on from their diagnosis with prostate cancer, taking into account the background mortality in the general population. It is therefore an estimate of the percentage of patients who survive their cancer for at least five years.

1,697

538

No.Cases/Deaths

Rate/%

86.3 ■

24.7 •

95.4 % •

86.3 %

79.9 % ■

UK avge

100.5

24.0

95.0 %

87.8 %

82.2 %

Five-year relative survival estimate (%) based on people diagnosed during 2000-2004. Relative survival estimates shown above are not age-standardised.

Source: National Cancer Intelligence Network (NCIN), UK Cancer Information Service (UKCIS), accessed May 2011. For more detailed information and definitions please see the <u>Cancer e-Atlas Guide</u>.





# National Cancer Intelligence Network Cancer survival in England by stage

www.ncin.org.uk



Figure 2, one-year survival, all stage, by year of diagnosis, not standardised by age







Figure 4 One-year relative/net survival, by stage, in the ICBP and England 2012 data



#### **Conclusions**

- •The quality and range of clinically relevant data on cancer is increasing rapidly
- High quality population-based data can clearly drive clinical behavioural change
- •We now have a large and expanding clinical community engaged with cancer data
- •Feedback and ongoing interaction with clinicians is an essential part of the process peer pressure is powerful
- There is a need to improve how information is used at a local level
- •The collection and intelligent use of data are at the heart of good clinical practice and commissioning



### **Local Cancer Intelligence**






Produced by Public Health England's National Cancer Intelligence Network and Macmillan Cancer Support

The cancer story is changing. There are more than 2 million people living with or beyond cancer in the UK today. By 2030 there will be 4 million.

Local Cancer Intelligence helps you understand your changing cancer population. It details what the changing cancer story means for your area by giving you headline information on numbers, needs and experiences. It includes:

- Prevalence
- Incidence
- Mortality
- Survival
- Patient experience
- Routes to and from diagnosis



#### FAQ

Click here to view or download all FAQs

Local Cancer Intelligence is a collaboration between Macmillan Cancer Support and Public Health England's National Cancer Intelligence Network (NCIN), combining the best data and insights from NCIN, Macmillan